Conclusions Ezetimibe monotherapy ( 10 mg/day ) showed a small ( 7.06 % ) but statistically significant reduction in the plasma levels of Lp(a ) in patients with primary hypercholesterolemia .
According to current literature , this magnitude of reduction seems to have no clinical relevance .
Background and Aims Ezetimibe reduces plasma low-density lipoprotein cholesterol ( LDL-C ) levels by up to 20 % .
However , its effect on plasma lipoprotein(a ) [ Lp(a ) ] concentrations in patients with primary hypercholesterolemia has not been defined .
Objective Therefore , we performed a systematic review and meta- analysis to assess this effect based on the available r and omized controlled trials ( RCTs ) .
Renal and vascular protective effects of ezetimibe in chronic kidney disease.
OBJECTIVE Dyslipidemia is a risk factor for not only cardiovascular diseases ( CVD ) , but also chronic kidney disease ( CKD ) . Ezetimibe , a cholesterol absorption inhibitor , lowers cholesterol levels by inhibiting both extrinsic and intrinsic cholesterol absorption via the gastrointestinal duct . However , very few studies have examined its efficacy and safety for patients with dyslipidemia complicated with CKD . METHODS Thirty-seven dyslipidemic patients ( low density lipoprotein cholesterol ( LDL-C ) levels ≥120 mg/dL ) complicated with CKD were given ezetimibe ( 10 mg/day ) for twenty-four weeks . The efficacy and safety of the therapy , including the anti-atherosclerotic and renal protective effects , were then examined . RESULTS Significant decreases were observed in the levels of LDL-C ( 158.9 ± 26.9 mg/dL→123.0 ± 31.8 mg/dL ; p<0.0001 ) , remnant-like lipoprotein cholesterol ( 9.3 ± 5.3 mg/dL→7.3 ± 3.8 mg/dL ; p<0.05 ) and lipoprotein ( a ) ( 22.0 ± 16.1 mg/dL→16.4 ± 11.0 mg/dL ; p<0.01 ) . The estimated glomerular filtration rate did not change , but the urine protein to creatinine ratio decreased significantly ( 1,107.3 ± 1,454.2 mg/gCre→732.1 ± 1,237.8 mg/gCre ; p<0.05 ) . No changes were observed in the carotid intima media thickness , but the brachial-ankle pulse wave velocity decreased significantly ( 1,770.4 ± 590.3 cm/sec→1,702.5 ± 519.9 cm/sec ; p<0.05 ) . No adverse events were observed . CONCLUSION Ezetimibe can be safely administered even to patients with CKD . The results of this study indicate that ezetimibe may provide some renal protection and suppress the complications of CVD in CKD patients
Conclusions Ezetimibe monotherapy ( 10 mg/day ) showed a small ( 7.06 % ) but statistically significant reduction in the plasma levels of Lp(a ) in patients with primary hypercholesterolemia .
According to current literature , this magnitude of reduction seems to have no clinical relevance .
Background and Aims Ezetimibe reduces plasma low-density lipoprotein cholesterol ( LDL-C ) levels by up to 20 % .
However , its effect on plasma lipoprotein(a ) [ Lp(a ) ] concentrations in patients with primary hypercholesterolemia has not been defined .
Objective Therefore , we performed a systematic review and meta- analysis to assess this effect based on the available r and omized controlled trials ( RCTs ) .